Technical Analysis for TARS - Tarsus Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Multiple of Ten Bullish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Multiple of Ten Bullish | Other | -3.07% | |
Wide Bands | Range Expansion | -3.07% | |
Oversold Stochastic | Weakness | -3.07% | |
50 DMA Support | Bullish | 4.01% | |
Multiple of Ten Bearish | Other | 4.01% | |
Wide Bands | Range Expansion | 4.01% | |
Oversold Stochastic | Weakness | 4.01% |
Alert | Time |
---|---|
Down 5% | about 12 hours ago |
Fell Below Previous Day's Low | about 12 hours ago |
60 Minute Opening Range Breakdown | about 13 hours ago |
Down 3% | about 16 hours ago |
Down 2 % | about 16 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/27/2024
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 40.4 |
52 Week Low | 11.33 |
Average Volume | 746,052 |
200-Day Moving Average | 20.36 |
50-Day Moving Average | 29.25 |
20-Day Moving Average | 33.56 |
10-Day Moving Average | 32.51 |
Average True Range | 2.19 |
RSI (14) | 46.24 |
ADX | 32.78 |
+DI | 20.65 |
-DI | 26.48 |
Chandelier Exit (Long, 3 ATRs) | 33.82 |
Chandelier Exit (Short, 3 ATRs) | 35.00 |
Upper Bollinger Bands | 39.79 |
Lower Bollinger Band | 27.33 |
Percent B (%b) | 0.26 |
BandWidth | 37.11 |
MACD Line | 0.35 |
MACD Signal Line | 1.27 |
MACD Histogram | -0.9221 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 32.88 | ||||
Resistance 3 (R3) | 32.87 | 32.10 | 32.50 | ||
Resistance 2 (R2) | 32.10 | 31.53 | 32.11 | 32.37 | |
Resistance 1 (R1) | 31.36 | 31.17 | 30.98 | 31.37 | 32.25 |
Pivot Point | 30.59 | 30.59 | 30.40 | 30.60 | 30.59 |
Support 1 (S1) | 29.85 | 30.02 | 29.47 | 29.86 | 28.97 |
Support 2 (S2) | 29.08 | 29.66 | 29.09 | 28.85 | |
Support 3 (S3) | 28.34 | 29.08 | 28.72 | ||
Support 4 (S4) | 28.35 |